Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) missed earnings with its latest annual results, disappointing overly-optimistic forecasters. Unfortunately, Arcturus Therapeutics Holdings ...

In a report released today, Yanan Zhu from Wells Fargo maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a price target of $50.00. The company’s shares closed ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Arcturus Therapeutics (ARCT) on Thursday reported a loss of $30 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a ...

ARCT has been the subject of several research analyst reports. HC Wainwright reiterated a “buy” rating and set a $63.00 target price on shares of Arcturus Therapeutics in a research note on ...

Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report)‘s stock had its “overweight” rating reiterated by Cantor Fitzgerald in a research report issued on Friday,Benzinga reports.